Pharmacy Methadone Dispensing Shows Strong Return on Investment

A new economic analysis published in JAMA Network Open finds that pharmacies offering medication-assisted treatment for opioid use disorder through methadone dispensing models are not just viable, they’re profitable.

The findings could reshape how communities access one of the most effective treatments available for opioid dependence.

Why Medication-Assisted Treatment Access Matters

Methadone is a cornerstone of medication-assisted treatment for opioid use disorder (OUD). It significantly reduces the risk of fatal overdose and all-cause mortality.

Yet under current federal law, methadone for OUD can only be dispensed through federally certified opioid treatment programs (OTPs). There are approximately 2,100 OTPs in the US, but 80% of counties, and the entire state of Wyoming, lack even one.

That access gap has life-or-death consequences. Patients in rural areas may need to travel nearly two hours each way for a daily methadone dose, a barrier that often causes people to abandon treatment entirely. Distance from home to treatment is directly associated with lower treatment retention.

The new study from Brandeis University and Boston University examined whether community pharmacies, already a trusted part of the healthcare system, could step into this gap, and whether doing so would make financial sense for pharmacy owners.

What the Study Found

Researchers modeled two distinct pharmacy-based methadone delivery approaches and ran 10,000 Monte Carlo simulations to stress-test the economics under a wide range of assumptions.

Model 1: Pharmacy-Based Medication Unit

In this approach, a pharmacy partners with an existing OTP to operate a satellite dispensing location. OTP clinicians prescribe the methadone; the pharmacist dispenses it on-site.

Over three years, the medication unit model returned $3.53 for every $1.00 spent, yielding a net profit of $96,904, with a 93.8% likelihood of netting at least $15,000 by year three.

Model 2: Pharmacist-Dispensed Methadone

This model would require changes to federal DEA regulations or the Controlled Substances Act, allowing any licensed prescriber to write a methadone prescription that a pharmacist fills, the same way methadone for pain is already handled.

This model returned $2.64 for every $1.00 spent, with a net profit of $23,844 over three years and a 97.6% probability of reaching the $15,000 profit threshold.

Both models showed positive returns on investment even under conservative assumptions. Notably, even in worst-case scenario analyses, with higher costs and lower revenue, both models remained more likely to turn a profit than not.

The Business Case for Expanding Detox Programs

The economic argument matters for a specific reason: pharmacies across the country are closing, with rural and independent pharmacies hit hardest.

These closures have disproportionately affected independent pharmacies, those in rural areas, and those serving low-income neighborhoods, the same communities where OTP access is most limited and opioid overdose rates are often highest.

The study authors note that almost 50% of rural census tracts have a community pharmacy within a 20-minute drive, a stark contrast to the hours-long trips many rural patients make to reach an OTP.

Pharmacies already dispense buprenorphine (Suboxone) and naltrexone for OUD and distribute naloxone for overdose reversal. Adding methadone dispensing would extend an existing clinical infrastructure rather than build something from scratch.

Understanding Methadone in MAT

Methadone is a long-acting opioid agonist, meaning it activates the same receptors as illicit opioids but in a controlled, sustained way that eliminates withdrawal symptoms and cravings without producing euphoria at therapeutic doses.

It has been a frontline medication-assisted treatment for opioid use disorder for decades and has a stronger evidence base for reducing overdose death than almost any other intervention.

Unlike buprenorphine, methadone currently cannot be prescribed and filled at a retail pharmacy for OUD, a regulatory restriction unique to the United States that many clinicians have called outdated.

What Needs to Change

Model 1, the medication unit approach, is already legal under federal law but rarely used.

Barriers include unclear and cumbersome regulations requiring methadone for OUD to be delivered to the pharmacy by the OTP and stored in a system separate from all other controlled substances. The study notes that removing these requirements alone would improve the financial picture further.

Model 2 would require either DEA regulatory action or a change to the Controlled Substances Act to permit licensed clinicians to prescribe methadone for OUD at a standard pharmacy.

The authors recommend that the DEA and SAMHSA move toward expanding pharmacy certification for methadone dispensing.

State governments also have a role to play. The research suggests states could use opioid settlement funds to incentivize OTP-pharmacy partnerships, implement tiered dispensing fees that reward pharmacies in underserved areas, and recognize pharmacists as clinicians eligible to bill insurers for clinical services.

Finding Medication-Assisted Treatment Near You

For people currently dependent on opioids, medically supervised treatment is the safest and most effective path. Medical detox, particularly for opioids, should never be attempted alone.

Withdrawal, while rarely fatal for opioids alone, is dangerous in combination with other substances and is a leading trigger for relapse and fatal overdose, since tolerance drops rapidly during detox.

Search detox.com’s directory to find a verified detox center or call 800-996-6135(Sponsored) to speak with a treatment specialist today.